Clinical trials: Episodic Migraine Headache
Migraine
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic…
- Trial name
- NCT03488563
- Testing
- B244, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Migraine, Headache, Tension-Type
Integrative and Complementary Therapy for Episodic Migraine and Tension-type Headache
This study is a monocentric uncontrolled observational study to evaluate a 12-14 day inpatient stay in an internal medicine clinic for integrative and complementary medicine for patients with episodic migraine and/or episodic…
- Trial name
- NAMIKOS (NCT06764914)
- Testing
- integrative and complementary medicine
- Volunteers
- 130 people
- Sponsor
- Kliniken Essen-Mitte
Migraine Disorders
Treatment of Episodic Migraine With AURICular Neuromodulation
Migraine is a ubiquitous pathology affecting approximately 1 billion individuals and being the leading cause of morbidity worldwide before the age of 50.
- Trial name
- MENAURIC (NCT06623188)
- Testing
- Auricular neuromodulation
- Where
- 3 sites in France
- Volunteers
- 106 people
- Sponsor
- Hôpital Européen Marseille
Migraine, Healthy
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects.
- Trial name
- NCT01970943
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Migraine, Pain
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients
Vasoactive intestinal peptide (VIP) is a peptide of 28 amino acid residues that belongs to the glucagon/secretin superfamily of peptides.
- Conditions
- Migraine, Pain, Neurologic Manifestations, Signs and Symptoms
- Trial name
- NCT04260035
- Testing
- Vasoactive Intestinal Polypeptide (VIP), Sterile saline
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Danish Headache Center
Migraine
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine
This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical…
- Trial name
- A-MI-01 (NCT07279623)
- Testing
- INMEST-treatment
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Abilion Medical Systems AB
Migraine, Abdominal Pain
Migraine and Recurrent Abdominal Pain in Children
This study will evaluate a new model for assessing and treating migraine and recurrent abdominal pain in children. The model combines behavioral techniques such as relaxation training with biologic components such as thermal…
- Trial name
- NCT00060619
- Testing
- thermal biofeedback, relaxation training, cognitive coping skills
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Migraine
Statin/Vitamin D & Migraine Study
The investigators are studying if taking simvastatin and vitamin D together will help prevent episodic migraines. Simvastatin is an FDA approved drug that is typically used to treat high cholesterol and reduce the risk of stroke…
- Trial name
- NCT01225263
- Testing
- Simvastatin, Vitamin D
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Rami Burstein
Chronic Migraine or Episodic Migraine
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
- Trial name
- NCT03238781
- Testing
- AMG 301
- Where
- 49 sites in United States, Austria and 6 more
- Volunteers
- 343 people
- Sponsor
- Amgen
Migraine
Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity and duration of headache. Flunarizine and topiramate are widely used in the prevention of migraine attacks.
- Trial name
- NCT03712917
- Testing
- Greater Occipital Nerve Block, Topiramate, Flunarizine
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Ataturk University
Migraine, Episodic Migraine
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
- Conditions
- Migraine, Episodic Migraine, Phonophobia, Photophobia
- Trial name
- NCT05207865
- Testing
- Rimegepant
- Where
- 19 sites in United States
- Volunteers
- 441 people
- Sponsor
- Pfizer
Migraine Disorders, Chronic Migraine
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments
Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group.
- Conditions
- Migraine Disorders, Chronic Migraine, Episodic Migraine
- Trial name
- SPHERA_WP2 (NCT06562400)
- Testing
- Palmitoyl ethanolamide, Ketogenic diet
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Migraine With Aura, Migraine Without Aura
Preventive Treatment of Episodic and Chronic Migraine
This is an open label pilot study to determine whether milnacipran can reduce headache frequency in episodic and chronic migraine sufferers.
- Conditions
- Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- NCT01319825
- Testing
- milnacipran
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- California Medical Clinic for Headache
Resistant Migraine, Chronic Migraine Headache
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant…
- Conditions
- Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
- Trial name
- RECLAIM-II (NCT07719608)
- Testing
- Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Salvia BioElectronics
Chronic Migraine
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients
Preclinical and clinical evidence suggests a role for the dysregulation of endocannabinoid system (ES) in migraine pain, particularly in subjects with chronic migraine.
- Trial name
- NCT04324710
- Where
- Italy
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Double-blind Design, Sham-controlled
Neurostimulation in Chronic and Episodic Migraine
Currently, successful prevention of migraine is not sufficiently achieved by (prophylactic) drug therapy. In contrast, neurophysiologically guided treatments might provide an alternative avenue, since these can normalize brain…
- Conditions
- Double-blind Design, Sham-controlled, Randomized
- Trial name
- NCT03237754
- Testing
- tDCS device from neuroConn
- Where
- Switzerland
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Chronic Migraine, High Frequency Episodic Migraine
The RECLAIM Study.
The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.
- Trial name
- RECLAIM (NCT06450444)
- Testing
- PRIMUS
- Where
- 11 sites in Australia, Belgium and 1 more
- Volunteers
- 110 people
- Sponsor
- Salvia BioElectronics
Episodic Migraine
Cerebri Biofeedback Feasibility Trial
The purpose of this study is to investigate feasibility, usability, safety, efficacy, and tolerability of Cerebri biofeedback treatment for adults with episodic migraine.
- Trial name
- CER-MIG-1 (NCT05454319)
- Testing
- Biofeedback
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Nordic Brain Tech AS
High Frequency Episodic Migraine and Chronic Migraine
"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"
Migraine, a complex and multifaceted disorder, remains only partially understood, with therapeutic strategies often limited by individual variability in response.
- Trial name
- NCT06692088
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Migraine With Aura, Migraine Without Aura
Trial Designs for Evaluating Migraine Treatment
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided.
- Conditions
- Migraine With Aura, Migraine Without Aura, Headache, Migraine
- Trial name
- NCT06617832
- Testing
- Active drug for acute migraine treatment
- Where
- 2 sites in Denmark
- Volunteers
- 128 people
- Sponsor
- University of Aarhus